A blockbuster AstraZeneca drug could now be used as an earlier remedy for mantle cell lymphoma (MCL), making it the primary in its class permitted as a first-line remedy for this uncommon and aggressive kind of blood most cancers.
The FDA expanded approval of the drug, acalabrutinib, to incorporate beforehand untreated MCL in adults who’re additionally ineligible for a hematopoietic stem cell transplant that may be a remedy possibility for youthful sufferers. As a first-line remedy, the AstraZeneca drug have to be utilized in mixture with bendamustine and rituximab, a drug routine usually used for older MCL sufferers. The late Thursday regulatory choice additionally grants conventional approval to the drug as a single-agent remedy for adults whose MCL has obtained an earlier line of remedy.
MCL is kind of B cell non-Hodgkin lymphoma, a most cancers of the lymphatic system. Chemotherapy is the usual remedy, however relapse is frequent. Acalabrutinib, marketed below the model title Calquence, is a small molecule designed to dam Bruton’s tyrosine kinase (BTK), an enzyme that promotes the proliferation and survival of malignant B cells.
Calquence, a twice-daily capsule, initially received accelerated FDA approval in 2017 as a remedy for adults whose MCL has obtained a minimum of one prior remedy. In 2019, the AstraZeneca drug’s label expanded to incorporate power lymphocytic leukemia or small lymphocytic leukemia. Calquence is one among AstraZeneca’s prime oncology merchandise, accounting for $2.5 billion in income in 2023, up 25% from the prior yr.
The newest FDA approval for Calquence relies on the outcomes of ECHO, a Part 3 examine that enrolled 598 sufferers age 65 and older with untreated MCL. These contributors have been randomly assigned to obtain the examine drug plus the bendamustine/rituximab routine, or a placebo and bendamustine/rituximab.
At a median follow-up of 49.8 months, scientific trial outcomes confirmed longer progression-free survival that was statistically vital. Median progression-free survival was 66.4 months within the examine drug arm versus 49.6 months within the comparator group. The Part 3 knowledge have been offered final June in the course of the annual assembly of the European Hematology Affiliation in Madrid.
“Managing this aggressive most cancers requires maximizing efficacy whereas sustaining tolerability, particularly for aged sufferers,” Michael Wang, director of the Mantle Cell Lymphoma Program of Excellence at MD Anderson Most cancers Heart and principal investigator within the trial, mentioned in a ready assertion included in AstraZeneca’s approval announcement. “Outcomes from the pivotal ECHO trial spotlight the promise of the acalabrutinib mixture in defining a brand new normal of care, with right this moment’s approval underscoring the transformative potential of this routine as a first-line remedy for older sufferers with mantle cell lymphoma.”
Calquence’s new FDA approval makes it the primary BTK inhibitor permitted as a first-line MCL remedy. That offers the drug an edge over others in its class. Eli Lilly’s BTK inhibitor, Jaypirca, landed FDA approval in 2023 as a third-line remedy for MCL. Imbruvica, marketed by Johnson & Johnson and AbbVie, and Brukinsa, from BeiGene (which is altering its title to BeOne Medicines), are each permitted as second-line remedies for MCL.
Picture: Christopher Furlong, Getty Pictures
